CA1324960C - Fabrication d'un produit pour le traitement du psoriasis et mode d'application - Google Patents
Fabrication d'un produit pour le traitement du psoriasis et mode d'applicationInfo
- Publication number
- CA1324960C CA1324960C CA 565548 CA565548A CA1324960C CA 1324960 C CA1324960 C CA 1324960C CA 565548 CA565548 CA 565548 CA 565548 A CA565548 A CA 565548A CA 1324960 C CA1324960 C CA 1324960C
- Authority
- CA
- Canada
- Prior art keywords
- ointment
- process according
- vitamin
- psoriasis
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title description 4
- 229940079593 drug Drugs 0.000 title description 4
- 201000010099 disease Diseases 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
- 239000003246 corticosteroid Substances 0.000 claims abstract description 20
- 229960001334 corticosteroids Drugs 0.000 claims abstract description 17
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000002674 ointment Substances 0.000 claims description 40
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 22
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 20
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 17
- 229930182566 Gentamicin Natural products 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 239000007764 o/w emulsion Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 claims description 11
- 229940108325 retinyl palmitate Drugs 0.000 claims description 11
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 11
- 239000011769 retinyl palmitate Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 10
- 229960004889 salicylic acid Drugs 0.000 claims description 10
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- 230000002045 lasting effect Effects 0.000 claims description 4
- 239000004519 grease Substances 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000839 emulsion Substances 0.000 abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 150000003873 salicylate salts Chemical class 0.000 abstract description 3
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000009291 secondary effect Effects 0.000 description 2
- LINZZISWCNKFEM-UHFFFAOYSA-N 3,3-dimethylbutanamide Chemical compound CC(C)(C)CC(N)=O LINZZISWCNKFEM-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960003950 combination of corticosteroids Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 565548 CA1324960C (fr) | 1988-04-29 | 1988-04-29 | Fabrication d'un produit pour le traitement du psoriasis et mode d'application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 565548 CA1324960C (fr) | 1988-04-29 | 1988-04-29 | Fabrication d'un produit pour le traitement du psoriasis et mode d'application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1324960C true CA1324960C (fr) | 1993-12-07 |
Family
ID=4137934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 565548 Expired - Fee Related CA1324960C (fr) | 1988-04-29 | 1988-04-29 | Fabrication d'un produit pour le traitement du psoriasis et mode d'application |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1324960C (fr) |
-
1988
- 1988-04-29 CA CA 565548 patent/CA1324960C/fr not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kragballe et al. | Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris | |
| WO1991008733A1 (fr) | Bases stables de creme et de lotion pour medicaments lipophiles | |
| NO175350B (no) | Fremgangsmåte for fremstilling av et topisk krempreparat for behandling av betennelse | |
| EP1474119A1 (fr) | Utilisation d'extraits contenant des phytooestrogenes modulant de maniere selective le recepteur beta d'oestrogenes | |
| EP0504403A1 (fr) | Composition therapeutique topique | |
| EP0765663A2 (fr) | Utilisation du diénogest pour la fabrication d'un médicament pour le traitement de la peau par application topique | |
| AU602871B2 (en) | Procedure for obtaining the preparation for the treatment of the disease psoriasis; drug for the treatment of psoriasis and its application | |
| RU2117479C1 (ru) | Фармацевтическая композиция | |
| CA1324960C (fr) | Fabrication d'un produit pour le traitement du psoriasis et mode d'application | |
| USRE36606E (en) | Synergistic pharmaceutical compositions | |
| EP0196121A1 (fr) | Procédé pour obtenir la préparation pour le traitement de la maladie psoriasis; médicament pour le traitement du psoriasis et son applicatioN | |
| US4299828A (en) | Corticosteroid stick formulations | |
| JP2005139210A (ja) | 乾癬治療 | |
| BG107042A (bg) | Двойни инхибитори на синтезата на холестеролов естер и восъчен естер, за лечение на разсройства на мастната жлеза | |
| Oranje et al. | Treatment of erythrodermic atopic dermatitis with “wet-wrap” fluticasone propionate 0.05% cream/emollient 1: 1 dressings | |
| KR20010073220A (ko) | 혈관수축 활성이 개선된 플루티카손 로션 | |
| JPS62155214A (ja) | 炎症治療薬及びそれによる炎症治療方法 | |
| Keita et al. | Pterygium popliteal syndrome concerning a case in the pediatric surgery department of the donka national hospital (Conakry CHU) | |
| HUE030408T2 (en) | Use of pidotimod for topical treatment of atopic dermatitis | |
| DE10247339A1 (de) | Psoriasisbehandlung | |
| Schmidt et al. | A double-blind trial of budesonide ointment and betamethasone-17-valerate ointment in psoriasis | |
| WO2004014396A9 (fr) | Medicament contenant de la fluocinolone et de la dexamethasone et/ou de l'hydrocortisone et de la gentamicine et/ou de la neomycine | |
| GB2050831A (en) | Corticosteroid stick formulations | |
| KR20010075720A (ko) | 프로필렌 글리콜 및 이소프로필 알칸산 에스테르를포함하는 항바이러스 제제 | |
| JPS63190897A (ja) | 乾癬治療用医薬組成物およびその製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |